EUVIMEDEUVIMED entdecken
Klinische Studie

Irreversible Electroporation-Assisted Resection for Locally Advanced Pancreas Cancer

Joshua Mk Davis iD, Patrick N Salibi, Benjamin M Motz, Dionisios Vrochides iD, Iain H McKillop iD, David A Iannitti

Surgical Innovation · 2023

DOI: 10.1177/15533506231157442 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Surgical Innovation, 2023. Verfasst von Joshua Mk Davis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hepato-Pancreato-Biliary Surgery, Atrium Health, Charlotte, NC, USA. Hauptthemen laut MEDLINE: Adenocarcinoma, Pancreatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A significant number of patients with advanced pancreatic cancer are unable to undergo resection due to vascular involvement. Irreversible electroporation (IRE) has shown promise in improving survival. This study sought to assess a novel IRE application whereby IRE was performed pre-resection to alter tissue plasticity and assist tumor removal from underlying vasculature when surgical excision was otherwise precluded.

Methods

After multidisciplinary evaluation appropriate patients were consented for IRE therapy. All IRE cases were tracked prospectively using an institutional review board-approved database that was retrospectively queried for patients undergoing IRE-assisted resection (IRE-AR) for pancreatic adenocarcinoma located in the head/uncinate process. Patients who underwent other IRE therapy or had disease location elsewhere were excluded.

Results

5 patients met the study inclusion criteria with a mean tumor size of 3.2 cm (range 2.4-4.1 cm). Using IRE-AR median recurrence free survival was 10.6 months, with 21.6 month overall survival. The average comprehensive complication index score was 23.23. One patient had grade 3 [or higher] complications and there were no 90 day mortalities.

Discussion

Employing a high-starting voltage for ablation along resection margins allows for resection when margins are anticipated to be positive. Patients with locally advanced pancreatic adenocarcinoma who underwent IRE-AR had promising outcomes.

Conclusion

This study reports IRE-AR as a novel approach for resecting locally advanced pancreatic adenocarcinoma. A prospective trial of IRE-AR for inoperable pancreatic adenocarcinoma will provide additional data for the long-term application of this approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaPancreatic NeoplasmsHumansElectroporationProspective StudiesRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

irreversible electroporation-assisted resectionpancreatic adenocarcinomavascular involvement

Autor:innen und Institutionen

  • Hepato-Pancreato-Biliary Surgery, Atrium Health, Charlotte, NC, USA.

ORCID-Profile: Joshua Mk Davis, Dionisios Vrochides, Iain H McKillop

Zitieren

APA

Davis, J. M., Salibi, P. N., Motz, B. M., Vrochides, D., McKillop, I. H., & Iannitti, D. A. (2023). Irreversible Electroporation-Assisted Resection for Locally Advanced Pancreas Cancer. Surgical Innovation. https://doi.org/10.1177/15533506231157442

Vancouver

Davis JM, Salibi PN, Motz BM, Vrochides D, McKillop IH, Iannitti DA. Irreversible Electroporation-Assisted Resection for Locally Advanced Pancreas Cancer. Surgical Innovation. 2023. doi:10.1177/15533506231157442

BibTeX
@article{Davis2023,
  author = {Davis, Joshua Mk and Salibi, Patrick N and Motz, Benjamin M and Vrochides, Dionisios and McKillop, Iain H and Iannitti, David A},
  title = {Irreversible Electroporation-Assisted Resection for Locally Advanced Pancreas Cancer},
  journal = {Surgical Innovation},
  year = {2023},
  doi = {10.1177/15533506231157442}
}
Kostenlos starten →